The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Bruce Jackson - The Benchmark Company - Analyst
: Hi, and good afternoon and congratulations on all of the progress. A couple of questions about the JIB Instrument Kit. Is this something that's being
prototype right now? And what are your plans in terms of getting into a full commercial availability and are there any regulatory considerations?
Question: Bruce Jackson - The Benchmark Company - Analyst
: Okay and super. And then in 2023, you had a fairly favourable reimbursement climate. Are there any changes for 2024 anticipated?
Question: Bruce Jackson - The Benchmark Company - Analyst
: Okay, great. And then a last question for me. We had a post-approval study underway. Just wanted to know if there's any update on that.
Question: Bruce Jackson - The Benchmark Company - Analyst
: Okay, Super. Thank you very much for taking the questions.
Question: Anthony Vendetti - Maxim Group, LLC - Analyst
: Thank you. Steve, yes, so it's just a follow-up on the on the post-market study of 40 to 50 patients and expect to conclude you said by end of 1Q
2024 to signed up today. What's the total number you have signed up so far?
Question: Anthony Vendetti - Maxim Group, LLC - Analyst
: Okay, great. And how many sites is that at just remind me again.
Question: Anthony Vendetti - Maxim Group, LLC - Analyst
: 7% okay. And then I know you do and physician training and obviously you've some great numbers here and procedures up 329% and the third
quarter. Are you ramping up the physician training ? How is that going? And what are you doing to get more physicians enrolled and aware of the
Catamaran System?
Question: Anthony Vendetti - Maxim Group, LLC - Analyst
: That's great. Just in terms of vetting them and figuring out, which orthopaedic surgeons you work with -- maybe just a little more color on how
that process goes. Is it referrals from KOLs ? How do you vet the orthopaedic surgeons to make sure that they're the right ones to train and work
with.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 14, 2023 / 9:30PM, TNON.OQ - Q3 2023 Tenon Medical Inc Earnings Call
Question: Anthony Vendetti - Maxim Group, LLC - Analyst
: Great. And then maybe just one financial question. So gross margin came in significantly better then, then I was expecting at 56.7%. Anything that
you would attribute that to that strong gross margin for this quarter? And is that sustainable or to fluctuate a little bit here in the near term? Thanks.
Question: Anthony Vendetti - Maxim Group, LLC - Analyst
: Okay. Great. Excellent. Thanks, guys. I'll hop back in the queue.
| 
